Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Business Wire•24/08/2026•16:05 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
